Lumida
/AGIO
⌘K
Agios Pharmaceuticals Inc

Agios Pharmaceuticals Inc

AGIO
$33.60USD-0.12%-0.04 today

MARKET CAP

2.0B

P/E (TTM)

FWD P/E

DAY RANGE

$33 – $34

52W RANGE

$22
$46

AI Summary

Stalk
Buy NowMedium

AGIO is in a pronounced lockout rally driven by forced participation, with price holding above rising EMAs and the 50-day SMA. The medium-term structure remains bullish as higher lows and upward-sloping EMAs support continuation. Long-term uptrend is intact, evidenced by price above the rising 200-day SMA. Despite price extension, lockout rally dynamics justify immediate entry on shallow pullbacks into EMA and SMA confluence. Key risks include a sudden reversal if EMAs fail to hold and exhaustion of forced buying.

  • Q2 '26 revenue rose to $44.7M, driven by Acvesme launch
  • 2026 U.S. PK deficiency sales guided at $45–50M
  • Negative earnings yield and unprofitable operations hamper valuation
Full analysis →
STATEMENT·Income statement
USD · GAAP
METRICFY 2020FY 2022FY 2023FY 2024FY 2025TREND
Sales, Adj.$0$14.2M$26.8M$36.5M$54.0M
YoY %+88.4%+36.1%+48.0%
P / Sales105.9x47.4x52.1x29.2x
EV / Sales105.8x48.8x53.4x29.5x
Gross Profit, Adj.$0$12.5M$23.9M$32.3M$47.7M
YoY %+91.0%+35.0%+47.5%
Margin %88.0%89.3%88.6%88.3%
EV / Gross Profit120.2x54.6x60.3x33.4x
EBITDA, Adj.$-317.1M$-380.5M$-384.9M$-420.1M$-467.0M
YoY %-2.9%-5.8%-1.2%-9.2%-11.2%
Margin %-2671.9%-1434.8%-1151.0%-864.3%
EV / EBITDA-10.5x-4.0x-3.4x-4.6x-3.4x
EBIT$-335.9M$-389.0M$-391.5M$-425.7M$-472.1M
YoY %-6.2%-2.8%-0.6%-8.7%-10.9%
Margin %-2732.1%-1459.5%-1166.5%-873.9%
EV / EBIT-9.9x-3.9x-3.3x-4.6x-3.4x
Net Income$-327.4M$-231.8M$-352.1M$673.7M$-412.8M
YoY %+20.4%-114.4%-51.9%+291.4%-161.3%
Net Margin-1627.8%-1312.6%1845.9%-764.0%
EPS (GAAP)-$4.74-$4.23-$6.33$11.64-$7.12
YoY %+30.9%-115.9%-49.6%+283.9%-161.2%